Another honor! Medicilon won the “Top 50 Chinese Pharmaceutical R&D” in 2022-2023

On July 4th, the Press Conference of the 2022-2023 Most Influential List of China’s Pharmaceutical Industry hosted by the All-China Federation of Industry and Commerce, Pharmaceutical Industry Chamber of Commerce was held in Harbin.  The press conference released the most influential list of China’s pharmaceutical industry in 2022-2023.  Medicilon once again won the “Top 50 Chinese Pharmaceutical R&D” in 2022-2023 based on its comprehensive strength.

The “Most Influential List of China’s Pharmaceutical Industry” by the All-China Federation of Industry and Commerce (ACFIC), Pharmaceutical Chamber of Commerce has become one of the authoritative lists of Chinese pharmaceutical industry.  The ACFIC invited first-class Chinese experts to form a selection team.  The selection adheres to the principles of open collection, objective data, strict screening, and fair selection.  United with a number of well-known Chinese media, focusing on the comprehensive capabilities of participating companies in terms of R&D professional capabilities, integrated service capabilities, professional R&D talent teams and quality assurance system, and good reputation, the 2022-2023 annual list of the most influential series in the pharmaceutical industry will be finally selected.